bcl 2 tr fret assay kit  (BPS Bioscience)

Journal: Frontiers in Immunology

Article Title: A novel carboxamide bromodomain inhibitor attenuates osteoarthritis via epigenetic repression of NF-κB and MAPK signaling

doi: 10.3389/fimmu.2025.1633334

Figure Lengend Snippet: NCD selectively binds to BRD2 (A) Schematic representation of the DNA-encoded library (DEL) screening process. Purified target proteins were incubated with the DEL standard library. DNA-tagged compounds that bound to the target were isolated, amplified by PCR, and identified using next-generation sequencing. (B, C) Schematic and quantitative results of the TR-FRET assay using NCD. A lower TR-FRET signal indicates stronger binding to the bromodomain (BD), as it prevents the probe from binding to the ligand. NCD exhibited selective binding, with reduced TR-FRET signals observed for BRD2, indicating high affinity. (D, E) Schematic and results of the binding kinetics assay using a biosensor. Binding affinities (KD values) of NCD for the bromodomains of BRD2–4 were measured. Lower KD values indicate stronger binding affinity, with NCD showing the highest affinity for BRD2.

Article Snippet: TR-FRET assays were conducted using kits specific for BRD2 (BD1 + BD2), BRD3 (BD1 + BD2), and BRD4 (BD1 + BD2) obtained from BPS Bioscience (San Diego, CA, USA).

Techniques: Purification, Incubation, Isolation, Amplification, Next-Generation Sequencing, Binding Assay